Going back to pre-2016 restrictions around the abortion drug Mifeprex — which a federal appeals court now seeks to do — would set off a cascade of problems that could take months, if not longer, to work out and cause the drug to be misbranded in the meantime, according to FDA Principal Deputy Commissioner Janet Woodcock.
Source: Drug Industry Daily